JP2023525991A5 - - Google Patents
Info
- Publication number
- JP2023525991A5 JP2023525991A5 JP2022567223A JP2022567223A JP2023525991A5 JP 2023525991 A5 JP2023525991 A5 JP 2023525991A5 JP 2022567223 A JP2022567223 A JP 2022567223A JP 2022567223 A JP2022567223 A JP 2022567223A JP 2023525991 A5 JP2023525991 A5 JP 2023525991A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- polypeptide sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021215P | 2020-05-07 | 2020-05-07 | |
| US63/021,215 | 2020-05-07 | ||
| US202062706131P | 2020-08-03 | 2020-08-03 | |
| US62/706,131 | 2020-08-03 | ||
| US202063198420P | 2020-10-16 | 2020-10-16 | |
| US63/198,420 | 2020-10-16 | ||
| US202063131394P | 2020-12-29 | 2020-12-29 | |
| US63/131,394 | 2020-12-29 | ||
| PCT/US2021/031055 WO2021226321A2 (en) | 2020-05-07 | 2021-05-06 | Anti-tumor associated antigen antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023525991A JP2023525991A (ja) | 2023-06-20 |
| JP2023525991A5 true JP2023525991A5 (cg-RX-API-DMAC7.html) | 2024-05-20 |
| JP7821121B2 JP7821121B2 (ja) | 2026-02-26 |
Family
ID=78468388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567223A Active JP7821121B2 (ja) | 2020-05-07 | 2021-05-06 | 抗腫瘍関連抗原抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230220107A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4146702A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7821121B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230007452A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115515981A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021267893A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022020716A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173176A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297955A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013920A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021226321A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| KR20240013094A (ko) | 2021-03-17 | 2024-01-30 | 마이얼로이드 테라퓨틱스, 인크. | 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법 |
| EP4605425A1 (en) * | 2022-10-18 | 2025-08-27 | Zymeworks BC Inc. | Antibody-drug conjugates targeting glypican-3 and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
| AU2008275985B2 (en) * | 2007-07-17 | 2013-09-19 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against Glypican-3 |
| US9206257B2 (en) * | 2011-04-19 | 2015-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| JP2017522861A (ja) * | 2014-05-22 | 2017-08-17 | ジェネンテック, インコーポレイテッド | 抗gpc3抗体及びイムノコンジュゲート |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TW201713700A (zh) * | 2015-05-27 | 2017-04-16 | 台灣泰福生技股份有限公司 | 抗glypican-3抗體及其用於診斷及治療癌症之用途 |
| EP3431102A4 (en) * | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY |
| CN109153719B (zh) * | 2016-03-15 | 2022-12-30 | 中外制药株式会社 | 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法 |
| WO2017162587A1 (en) * | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| CN118421557A (zh) * | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| EP3551220B1 (en) * | 2016-12-07 | 2025-01-29 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| EP3615574B1 (en) * | 2017-04-26 | 2026-06-24 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| JP7382922B2 (ja) * | 2017-09-20 | 2023-11-17 | 中外製薬株式会社 | Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン |
| AR114112A1 (es) * | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| CN111040036B (zh) * | 2018-10-12 | 2023-10-20 | 上海卡智生物技术有限公司 | 抗gpc3单克隆抗体、由其修饰的免疫效应细胞及其应用 |
-
2021
- 2021-05-06 MX MX2022013920A patent/MX2022013920A/es unknown
- 2021-05-06 CN CN202180032994.3A patent/CN115515981A/zh active Pending
- 2021-05-06 IL IL297955A patent/IL297955A/en unknown
- 2021-05-06 CA CA3173176A patent/CA3173176A1/en active Pending
- 2021-05-06 JP JP2022567223A patent/JP7821121B2/ja active Active
- 2021-05-06 AU AU2021267893A patent/AU2021267893A1/en active Pending
- 2021-05-06 EP EP21800926.4A patent/EP4146702A4/en active Pending
- 2021-05-06 WO PCT/US2021/031055 patent/WO2021226321A2/en not_active Ceased
- 2021-05-06 US US17/997,755 patent/US20230220107A1/en active Pending
- 2021-05-06 KR KR1020227041924A patent/KR20230007452A/ko active Pending
- 2021-05-06 BR BR112022020716A patent/BR112022020716A2/pt unknown